Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Ovarian Low Malignant Potential Tumors
For general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Ovarian Epithelial Cancer
Related Summaries Note: Other PDQ summaries containing information related to ovarian epithelial cancer include the following: Genetics of Breast and Ovarian Cancer Ovarian Cancer Screening Ovarian Cancer Prevention Unusual Cancers of Childhood Statistics Note: Estimated new cases and deaths from ovarian cancer in the United States in 2010:[ 1 ] New cases: 21,880. Deaths: 13,850. Note: Some ...
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Changes to This Summary (04 / 12 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I and Stage II Ovarian Epithelial Cancer Treatment
Treatment options:If the tumor is well differentiated or moderately well differentiated, surgery alone may be adequate treatment for patients with stage IA and IB disease. Surgery should include hysterectomy, bilateral salpingo-oophorectomy, and omentectomy. Additionally, the undersurface of the diaphragm should be visualized and biopsied; pelvic and abdominal peritoneal biopsies and pelvic and para-aortic lymph node biopsies are required and peritoneal washings should be obtained routinely. In selected patients who desire childbearing and have grade I tumors, unilateral salpingo-oophorectomy may be associated with a low risk of recurrence.If the tumor is grade III, densely adherent, or stage IC, the chance of relapse and death from ovarian cancer is as much as 30%.[3,4,5,6] Clinical trials evaluating the following treatment approaches have been performed:Intraperitoneal P-32 or radiation therapy.[1,7,8]Systemic chemotherapy based on platinums alone or in combination with
Ovarian Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Evidence of Benefit
PathogenesisThe pathogenesis of ovarian carcinoma remains unclear. Several theories have been proposed to explain the epidemiology of ovarian cancer including the theory of incessant ovulation,[1,2] gonadotropin stimulation, excess androgenic stimulation, and inflammation. Associated risk factors for ovarian cancer support some or all of these hypotheses. Oral contraceptive use is consistently associated with a decreased risk of ovarian cancer and may operate through preventing the trauma from repeated ovulation by lowering exposure to gonadotropins. No one theory, however, explains all the associated risk factors.Protective Factors Factors associated with a decreased risk of ovarian cancer include: (1) using oral contraceptives, (2) having and breastfeeding children, (3) having a bilateral tubal ligation or hysterectomy, and (4) having a prophylactic oophorectomy.Oral contraceptives Multiple studies have consistently demonstrated a decrease in
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Ovarian Germ Cell Tumors
The following histologic subtypes have been described.[1,2]Dysgerminoma.Other germ cell tumors: Endodermal sinus tumor (rare subtypes are hepatoid and intestinal).Embryonal carcinoma.Polyembryoma.Choriocarcinoma.Teratoma: Immature.Mature: Solid.Cystic: Dermoid cyst (mature cystic teratoma).Dermoid cyst with malignant transformation.Monodermal and highly specialized: Struma ovarii.Carcinoid.Struma ovarii and carcinoid.Others (e.g., malignant neuroectodermal and ependymoma).Mixed forms.References: Gershenson DM: Update on malignant ovarian germ cell tumors. Cancer 71 (4 Suppl): 1581-90, 1993. Serov SF, Scully RE, Robin IH: International Histologic Classification of Tumours: No. 9. Histological Typing of Ovarian Tumours. Geneva: World Health Organization, 1973.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Ovarian Low Malignant Potential Tumors
Ovarian low malignant potential tumors may recur (come back) after they have been treated. The tumors may come back in the other ovary or in other parts of the body.
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Advanced-Stage Ovarian Low Malignant Potential Tumors
Patients with advanced disease should undergo a total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, node sampling, and aggressive cytoreductive surgery. Patients with stage III or IV disease with no gross residual tumor have had a 100% survival rate in some series regardless of the follow-up duration.[1,2] The 7-year survival rate of patients with gross residual disease was only 69% in a large series  and appears to be inversely proportional to the length of follow-up.For patients with more advanced-stage disease and microscopic or gross residual disease, chemotherapy and/or radiation therapy are not indicated. Scant evidence exists that postoperative chemotherapy or radiation therapy alters the course of this disease in any beneficial way.[1,3,4,5,6] In a study of 364 patients without residual tumor, adjuvant therapy had no effect on disease-free or corrected survival when stratified for disease stage. Patients without residual tumor who received no adjuvant
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Ovarian Low Malignant Potential Tumors
A link to a list of current clinical trials is included for each treatment section. For some stages, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Early Stage Ovarian Low Malignant Potential Tumors (Stage I and II)Surgery is the standard treatment for early stage ovarian low malignant potential tumor. The type of surgery usually depends on whether a woman plans to have children.For women who plan to have children, surgery is either:unilateral salpingo-oophorectomy; orpartial oophorectomy.To prevent recurrence of disease, most doctors recommend surgery to remove the remaining ovarian tissue when a woman no longer plans to have children.For women who do not plan to have children, treatment may be hysterectomy and bilateral salpingo-oophorectomy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage I borderline ovarian surface epithelial-stromal